Aarti Drugs is locked in upper circuit of 10% at Rs 210 on NSE after reporting a robust 86% year-on-year (y-o-y) jump in net profit at Rs 13.81 crore for the fourth quarter ended March 31, 2013.
The pharmaceutical company had reported a profit of Rs 7.41 crore in the year ago quarter. Net sales grew 10.6% at Rs 220 crore on y-o-y basis.
For the full financial year 2012-13, net profit more-than-doubled to Rs 45.24 crore against profit of Rs 22.46 crore in FY2011-12. Net sales surged 25% at Rs 826 crore from Rs 662 crore in previous year.
Meanwhile, the board has recommended a final dividend of Rs 4 per share on equity shares of Rs 10 each.
The stock opened at Rs 202 and has seen a combined 14,537 shares changing hands on the counter so far. There are pending buy orders for 9,683 shares on NSE and BSE at 0945 hours.
The pharmaceutical company had reported a profit of Rs 7.41 crore in the year ago quarter. Net sales grew 10.6% at Rs 220 crore on y-o-y basis.
For the full financial year 2012-13, net profit more-than-doubled to Rs 45.24 crore against profit of Rs 22.46 crore in FY2011-12. Net sales surged 25% at Rs 826 crore from Rs 662 crore in previous year.
Meanwhile, the board has recommended a final dividend of Rs 4 per share on equity shares of Rs 10 each.
The stock opened at Rs 202 and has seen a combined 14,537 shares changing hands on the counter so far. There are pending buy orders for 9,683 shares on NSE and BSE at 0945 hours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%